Parabilis MedicinesPBLS
Oncology7 cited findings · profile updated 2026-08-20
41.32 USDnot live — refreshed daily
About Parabilis Medicines
Parabilis Medicines (PBLS) is an oncology-focused research site. The company's pipeline includes Zolucatetide, which is currently in Phase 1/2 development. In studies, Zolucatetide demonstrated an Overall Response Rate (ORR) of 74%. Specific responses observed with Zolucatetide included a partial response of -48% and another partial response of -56%, alongside a tumor reduction of -19.2%. The drug also showed 20 RECIST 1.1 responses.
Another investigational agent in Parabilis Medicines' portfolio is the ERG degrader Helicons, which has shown a Tumor Growth Inhibition (TGI) ranging from 60–95%.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| ORR | 74% | Parabilis Medicines, Inc. — SEC 8-K (2026-08-13), p.4 |
| Partial response | -48% | Parabilis Medicines, Inc. — SEC 8-K (2026-08-13), p.7 |
| Partial response | -56% | Parabilis Medicines, Inc. — SEC 8-K (2026-08-13), p.7 |
| tumor reduction | -19.2% | Parabilis Medicines, Inc. — SEC 8-K (2026-08-13), p.7 |
| RECIST 1.1 responses | 20 | Parabilis Medicines, Inc. — SEC 8-K (2026-08-13), p.8 |
| TGI | 60–95% | Parabilis Medicines, Inc. — SEC 8-K (2026-08-13), p.8 |
Key projects
- Zolucatetide
Zolucatetide is in Phase 1/2 development.
- ERG degrader Helicons
ERG degrader Helicons demonstrated a TGI of 60–95%.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Oncology research library →